Authors:
Yusra F. Shao, Yasmine Baca, Joanne Xiu, Ari VanderWalde, Gino Kim In, Dave S. B. Hoon, Evidio Domingo-Musibay, Sourat Darabi, Burton Larry Eisenberg, Takami Sato, Geoffrey Thomas Gibney, Hirva Mamdani, Justin C Moser
Key Finding:
Biomarkers of immune checkpoint inhibitor response, like PD-L1 and tumor mutational burden, have low prevalence in uveal melanoma and are not associated with benefit from immune blockade.
Download PublicationCookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |